🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

17 results for “clostridium” Clear

  1. CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS, Placebo to Clostridium Botulinum neurotoxin type A (150 kD)

    Merz Therapeutics GmbH

    Episodic migraine

    phase 3 small molecule active

    1 trial

  2. Placebo to Clostridium Botulinum neurotoxin type A (150 kD), CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS

    Merz Therapeutics GmbH

    Chronic migraine

    phase 3 small molecule active

    1 trial

  3. SER-109

    Seres Therapeutics

    Clostridium Difficile Infection

    phase 3 mab completed

    1 trial

  4. CP101

    Finch Therapeutics Group

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  5. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  6. Full Spectrum Microbiota

    Finch Therapeutics Group

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule completed

    1 trial

  7. Ibezapolstat

    Acurx Pharmaceuticals

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule active

    1 trial

  8. Ibezapolstat

    Acurx Pharmaceuticals

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial

  9. Ridinilazole

    Summit Therapeutics

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial

  10. SER-109

    Seres Therapeutics

    Clostridium Difficile

    phase 2 small molecule completed

    1 trial

  11. SMT19969

    Summit Therapeutics

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial

  12. VP20621

    Takeda

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  13. SER-262

    Seres Therapeutics

    Clostridium Difficile Infection

    phase 1 small molecule completed

    1 trial

  14. Rifaximin

    United Therapeutics Europe Ltd

    Clostridium Difficile Infection

    approved small molecule completed

    1 trial

  15. Clostridium butyricum (live) Tablets(Meiya)

    Rocket Pharmaceuticals B.V.

    Rectal Cancer

    mab active

    1 trial

  16. Miyarisan-BM (Clostridium Butyricum Miyairi)

    Hospital Authority, Hong Kong

    Clostridium Butyricum Miyairi

    small molecule active

    1 trial

  17. Specific Carbohydrate Diet

    NORTHWEST BIOTHERAPEUTICS INC

    Clostridium Difficile Infection

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources